<DOC>
	<DOCNO>NCT01007578</DOCNO>
	<brief_summary>The purpose study determine plasma level paclitaxel catheter tolerability subsequent treating patient peripheral arterial occlusive disease ( PAOD ) paclitaxel-coated balloon catheter .</brief_summary>
	<brief_title>Drug-Eluting Balloon Catheters Treatment Peripheral Arterial Occlusive Disease</brief_title>
	<detailed_description>This open-labeled multicenter study investigate plasma level catheter tolerability follow application paclitaxel-coated balloon catheter angioplasty patient stenotic occlude femoro-popliteal artery due atherosclerosis . Safety assess change blood cell ( leukocytes , neutrophil thrombocyte ) count , change serum biochemistry parameter . Tolerability assess adverse event occurences relate paclitaxel-coating and/or device investigator .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients must meet follow criterion inclusion study : 1 . Clinically stable patient PAOD disease , Rutherford stage 1 , 2 , 3 , 4 , 5 . 2 . Occlusion 5 cm â‰¥70 % diameter stenosis 32 cm length Arteria ( A . ) femoralis superficialis A. popliteal , document angiography prior intervention . 3 . Age : &gt; 18 year . 4 . Guide wire may successfully advance across lesion . 5 . Patient eligible operative vascular intervention case complication . 6 . Informed consent sign patient information possible alternative . 7 . Women childbearing potential must negative result serum pregnancy test use reliable method contraception . Patients meet follow exclusion criterion include study : 1 . Previous treatment location . 2 . Close affiliation investigational site ; e.g. , close relative Investigator , dependent person ( e.g. , employee student investigational site ) . 3 . Acutely occur symptom ( within last 6 week ) lysis operation therapeutic option . 4 . Potential loss leg due ischemia . 5 . Distal blood flow less one low leg blood vessel . 6 . Aneurysm intend treatment blood vessel . 7 . Women child bear potential ( 2 year postmenopausal ) without negative pregnancy test . 8 . Manifest hyperthyreosis latent hyperthyreosis without previous blocking ( sodium phosphonate ) . 9 . Blood platelet count &lt; 100.000/mm^3 &gt; 700.000/mm^3 , leukocyte count &lt; 3.000/mm^3 . 10 . Known intolerance contraindication aspirin , heparin , clopidogrel , abciximab , paclitaxel , stainless steel , know intolerance contrast agent adequately pretreated . 11 . Illnesses ( cancer , liver disease , myocardial insufficiency ) lead protocol deviation reduce life expectancy ( &lt; 2 year ) . 12 . Renal insufficiency serum creatinine 2.0 mg/dL . 13 . Diabetes mellitus additional metformin therapy . 14 . Significant gastrointestinal hemorrhage previous 6 month . 15 . History hemorrhagic diathesis coagulopathy rejection blood transfusion due religious reason . 16 . Patient receive investigational device combination product intend indication within 30 day prior enter study . 17 . Patient previously participate another study use paclitaxel coat catheter . 18 . Noncompliant incapable patient participate study ( patient unable speak understand German language ) , patient willing answer question regard study via telephone , patient reject electronic storage patient information , imprison patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Paclitaxel-coated balloon catheter</keyword>
	<keyword>Peripheral arterial occlusive disease ( PAOD )</keyword>
	<keyword>Plasma level</keyword>
	<keyword>Femoral artery</keyword>
	<keyword>Popliteal artery</keyword>
	<keyword>Peripheral arterial disease ( PAD ) include stenotic occlude femoro-popliteal artery due atherosclerosis</keyword>
</DOC>